Rizvi N, et al. Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. Abstract OA04.07. WCLC 2019, 7-10 september, Barcelona, Spanje.
Pembrolizumab bij gemetastaseerd urotheelcarcinoom: resultaten na 5 jaar follow-up
feb 2023 | Immuuntherapie, Uro-oncologie